Pieris Pharmaceuticals, Inc. — Q1 2019 Form 10-Q
Period: Three months ended March 31, 2019; filed May 10, 2019. The filing identifies Pieris Pharmaceuticals, Inc. as the registrant. Pieris is a clinical-stage biopharmaceutical company developing Anticalin-based medicines; it had no product-sales revenue.
Financial performance and liquidity
| Metric | Q1 2019 | Q1 2018 |
|---|---|---|
| Revenue | $8.5 million | $4.2 million |
| Research and development expense | $14.3 million | $7.9 million |
| General and administrative expense | $4.9 million | $4.4 million |
| Operating loss | $10.7 million | $8.1 million |
| Net loss | $10.3 million | $8.7 million |
| Basic and diluted loss per share | $0.20 | $0.17 |
| Operating cash flow | $(15.1) million | $31.3 million provided |
At March 31, cash and cash equivalents were $52.1 million and short-term investments were $58.7 million, totaling $110.8 million. Current assets were $124.3 million and current liabilities $41.1 million. Total liabilities were $100.9 million, primarily deferred revenue; the balance sheet reports no debt balance. The company reported no off-balance-sheet arrangements.
Material changes and notable items
- Revenue more than doubled year over year, principally reflecting greater activity under the AstraZeneca collaboration and a full quarter of Seattle Genetics collaboration revenue. R&D expense rose by $6.4 million, mainly from immuno-oncology clinical and manufacturing costs and respiratory-program spending.
- Cash declined by $22.8 million during the quarter. Investing cash outflow was $5.3 million; there were no financing cash flows. The prior-year operating cash inflow reflected substantial collaboration-related receipts, while Q1 2018 financing included $47.2 million of stock issuance proceeds.
- Pieris adopted ASC 606 from January 1, 2019 using the modified retrospective method. Prior-period figures were not restated. The company’s pro forma ASC 605 comparison shows Q1 2019 revenue would have been $9.2 million and net loss $9.7 million, versus reported revenue of $8.5 million and net loss of $10.3 million. Adoption reduced opening equity by $1.6 million.
- BVF exchanged 5.0 million common shares for 5,000 Series B convertible preferred shares. The preferred shares are convertible into common stock, subject to ownership limits.
- Potential partnership milestone payments are substantial but contingent: the filing lists up to $2.85 billion in research, development and commercial milestones and $2.29 billion in sales milestones across Seattle Genetics, AstraZeneca and Servier arrangements. These are not committed or forecast revenue.
Outlook, risks and contingencies
- Management expects existing cash, cash equivalents and investments to fund operating and capital requirements for at least 12 months from the filing date. It expects substantial losses and increased cash needs as development advances; additional financing may be needed, with potential dilution or restrictions on shareholder rights.
- Planned or anticipated milestones include reporting PRS-343 clinical data in 2019; filing an IND for PRS-344 in the second half of 2019; and presenting PRS-080 Phase 2a data in June 2019. AstraZeneca funds PRS-060 Phase 1 work and is expected to fund its Phase 2a study. These are forward-looking plans, not guarantees.
- Key risks include clinical and regulatory uncertainty, dependence on collaborators and third parties, funding needs, foreign-exchange exposure, and the possibility that partners may terminate programs. Research and development milestones remain constrained until revenue recognition criteria are met.
- Disclosure controls and procedures were deemed ineffective at March 31, 2019 because of a previously identified material weakness in the income-tax provision process. Management reported remediation efforts and stated the weakness had not caused a financial-statement misstatement. No material legal proceedings were reported.
Investor verification priorities
- Confirm cash, investment maturities, quarterly burn rate and the assumptions supporting the stated 12-month runway.
- Assess how ASC 606 affects revenue timing and compare performance on a consistent accounting basis.
- Track clinical results, timelines and partner decisions for PRS-060, PRS-343, PRS-344 and PRS-080, including ASKA’s option decision.
- Review the status of the tax-control remediation and any subsequent disclosures about control effectiveness.
- Distinguish contingent milestone ceilings from achievable payments, and monitor collaboration funding, termination terms and potential financing or dilution.